Biose Industrie a republié ceci
really excited to see Adam Wilkinson from Microbiotica and my colleague Claire Derlot doing a joint presentation on the cmc journey of their 2 multi-strain LBPs.
Founded in 1951 by pharmacists and microbiologists, biose® has 60-year experience in drug based on live bacteria, giving us a deep understanding of the entire process from discovery to commercialization. Focused on Health through microbiota and microbiome science, we use our skills for the discovery, product development, clinical studies and manufacturing of Live Biotherapeutic Products (LBPs). Our company is drug-GMP certified for the manufacturing of bacteria-based APIs, clinical and commercial products.
Lien externe pour Biose Industrie
24 avenue Georges Pompidou
15000 Aurillac, FR
Boston, MA, US
Biose Industrie a republié ceci
really excited to see Adam Wilkinson from Microbiotica and my colleague Claire Derlot doing a joint presentation on the cmc journey of their 2 multi-strain LBPs.
Biose Industrie a republié ceci
Read the latest news about our manufacturing progress for our live biotherapeutic products (LBPs) targeting #melanoma and #ulcerativecolitis, being presented at the Microbiome Movement Drug Development Summit in Boston by Adam Wilkinson alongside Claire Derlot from our GMP manufacturing partner Biose Industrie. This milestone reflects the hard work and collaboration between Microbiotica and Biose Industrie, ensuring robust GMP manufacturing processes for our innovative therapies. Join us on July 11 at 9 AM to hear about the development and scale up of the manufacturing for our LBPs, MB097 and MB310, as we prepare for clinical trials later this year. 🔗Read our Press Release: https://lnkd.in/eEtdw6j6 #Biotech #Innovation #Microbiome
We are proud lead partners of the Hanson Wade Group 9th Microbiome Movement Drug Development Summit taking place in Boston, July 10-12. Don't miss our joint presentation by Adam Wilkinson and Claire Derlot focusing on the fruitful partnership of Microbiotica and Biose Industrie for the development and manufacturing of two multi-strain LBPs for clinical studies.
Claire Derlot talking at Microbiome connect in Seoul, Korea about LBP CMC development and Production for the 37 clinical lines being manufactured for our clients around the world.
Here we are !! https://lnkd.in/ghqEdks6
We're proud to announce that Taous SARAOUI-MAZED, our esteemed Head of Program, will be representing biose industrie at the upcoming International Probiotic Conference at Prague https://lnkd.in/eUuR4z_X. Join her to explore our latest innovations and strategies in the CMC field for the manufacturing and control of NGP / probiotics and LBPs. Don't miss this opportunity to gain insights from one of our top experts in microbiome health. #ProbioticsConference #Innovation #MicrobiomeHealth #BioseIndustrie #LBP #NGP #GMP
Biotechs often face challenges during the process of drug manufacturing. At Biose Industrie our approach is to work closely with the client to overcome these challenges and adjust to the requirements of each project in order to deliver innovative biopharmaceutical process solutions to accelerate project success. With over 100 batches per year and over 300 different strains in development, we are the world leader in the bioproduction of microbiome therapeutics and next generation probiotics.
#bioseindustrie at Probiota Americas !!!
🌍 Thrilled to kick off Probiota Americas 2024 in Salt Lake City! Join Richard Ellis, our Head of Business Development, and me at the biose industrie booth. We're here to exchange on our pioneering manufacturing solutions in live biotherapeutics and next-generation probiotics. Don't miss out on the opportunity to connect with us and discover how we can help you to shape the future of microbiome health. #ProbiotaAmericas2024 #Microbiomemanufacturing #BioseIndustrie #cdmo #NGP #probiotics #LBP
Last month, we attended The Microbiome Times Microbes in Women's Health Congress in Copenhagen where it was an absolute pleasure for our CEO Adrien Nivoliez, PhD - MBA to share the stage together with Jacques Ravel and Caroline Mitchell - two of the most prominent KOLs in the field. Together the trio presented the development of two multi-strain consortium LBPs targeting Bacterial Vaginosis, LC106 and LC115. Both drug products contain multiple strains of L. Crispatus, 6 strains and 15 strains respectively, identified in women with a very stable vaginal microbiota. The presentation covered various considerations for design, formulation, regulation, and manufacturing. Watch the presentation below here: We would also like to thank Sarah Lebeer for the warm welcome on stage :) https://lnkd.in/d5KuYbTY
I'll be at our Woburn laboratory just north of Boston this week and we'll be happy to meet with any body interested in developing LBPs or next generation probiotics. Message me if you'd like to meet the team. Adrien Nivoliez, PhD - MBA Nadine Daou https://www.biose.com/us/